...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Top-Line Data Expected September 2019 for BETonMACE Phase 3 Cardiovascular Outcomes Trial for Apabetalone

Message: Frustrating company no doubt, but it'll abe be worth it I think.....

Low volume no doubt, and now that we've seen short interest increase by over 190K in just the past month up to trades settled by July 15th it makes you realize that volume would have been EVEN LOWER had it not been for the borrowing and dumping back of shares.  

I'm not going to disregard the chart, but measuring it off against the fundamental realities (like the loan, the short time to Top-Line, short selling) helps define a more clear picture in my opinion.  I'm more bullish now than I've been at any time.

New Message
Please login to post a reply